Showing results (21-30 of 37) with videos related to
Sort By:
Pageof 4
AIDS Research and Human Retroviruses|October 18, 2012
Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort studySonia Napravnik, Joseph J Eron, Timothy R Sterling, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2013
Comparative incidence and health care costs of medically attended adverse effects among U.S. Medicaid HIV patients on atazanavir- or darunavir-based antiretroviral therapyStephen S Johnston, Timothy Juday, Stephen Esker, et al.Advances in Therapy|June 26, 2016
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United StatesSammy Saab, Suchin Virabhak, Hélène Parisé, et al.JAMA Internal Medicine|November 7, 2013
The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical RegistryJeffrey McCombs, Tara Matsuda, Ivy Tonnu-Mihara, et al.Journal of Medical Economics|July 12, 2012
Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapySteven-Huy Han, Wuhua Jing, Edward Mena, et al.Health Affairs (Project Hope)|March 5, 2014
Nearly 60,000 uninsured and low-income people with HIV/AIDS live in states that are not expanding MedicaidJulia Thornton Snider, Timothy Juday, John A Romley, et al.BMC Geriatrics|June 6, 2022
Falls, healthcare resources and costs in older adults with insomnia treated with zolpidem, trazodone, or benzodiazepinesDiana T Amari, Timothy Juday, Feride H Frech, et al.Health Affairs (Project Hope)|March 5, 2014
HIV care providers emphasize the importance of the Ryan White Program for access to and quality of careNeeraj Sood, Timothy Juday, Jacqueline Vanderpuye-Orgle, et al.Clinicoeconomics and Outcomes Research : CEOR|September 15, 2012
Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspectiveNaoky Tsai, Lennox Jeffers, Lael Cragin, et al.The American Journal of Managed Care|June 9, 2016
The wider public health value of HCV treatment accrued by liver transplant recipientsAnupam B Jena, Warren Stevens, Yuri Sanchez Gonzalez, et al.Pageof 4